Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Hematology
• Drug Development

Background:

• Limited availability of Factor VIII (FVIII) concentrates hinders Hemophilia A prophylaxis in resource-limited countries.
• Rondaptivon pegol (BT200), a pegylated aptamer, elevates von Willebrand Factor (VWF) and FVIII levels.
• Plasma-derived FVIII products are more accessible than recombinant ones in low-resource settings.

Purpose of the Study:

• To develop and evaluate a population pharmacokinetic/pharmacodynamic (PK/PD) model for BT200.
• To predict the efficacy of BT200 in combination with plasma-derived FVIII for Hemophilia A prophylaxis.
• To assess the potential of BT200 to reduce FVIII concentrate requirements.

Main Methods:

• A population PK model for BT200 was integrated with kinetic models of VWF and FVIII.
• The PK/PD model was developed using data from healthy volunteers and mild-to-moderate Hemophilia A patients.
• Model validation was performed using an external dataset from severe Hemophilia A patients.

Main Results:

• The developed PK/PD model accurately described BT200, VWF, and FVIII kinetics in various populations.
• Simulations predicted FVIII concentration-time profiles for coadministration of plasma-derived FVIII and BT200.
• A combination of 6 mg BT200 weekly and 10 IU/kg plasma-derived FVIII twice weekly achieved similar FVIII coverage to 30 IU/kg FVIII thrice weekly without BT200.

Conclusions:

• The PK/PD model effectively predicts BT200, VWF, and FVIII concentrations in Hemophilia A patients.
• BT200 in combination with plasma-derived FVIII can significantly reduce the required FVIII dose for prophylaxis.
• This combination therapy offers a promising strategy to improve Hemophilia A management in resource-limited regions.